Replies to post #218590 on Biotech Values

[jq1234]

Ok, I see you were talking about OS co-primary endpoint. The reason BMY selected that is most likely to preserve CheckMate-227 Part 1a trial (Nivolumab + ipilimumab vs Nivolumab vs chemo in PD-L1+) completely. In case PFS co-primary in TMB fails or regulators consider it post hoc, they at least have something to fall on based entirely on prespecificed portion of trial.